Stay updated on Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedAdded study locations in Ohio and Pennsylvania and updated the page revision to v3.3.3. Removed the HHS Vulnerability Disclosure and the previous Ohio and Pennsylvania location entries.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedPublications are described as auto-filled from PubMed, and the page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page no longer displays a site-wide government funding/operating status notice, which does not affect the trial data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedResults for the RELIVE study have been posted on the page, and the Study Record Dates now show a Results First Posted date of 2021-06-02.SummaryDifference0.2%

- Check89 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 release; removal of the old v3.1.0 tag.SummaryDifference2%

- Check96 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.